Several other markers have also been associated with poor prognosis in NSCLC (EGFR, CMET, E-cadherin, pAKT (Takanami et al, 1996; Bremnes et al, 2002; David et al, 2004; Deeb et al, 2004; Masuya et al, 2004a)), but at present there is no single marker that can be used to guide therapy or predict prognosis of NSCLC patients. The gene discussed is MET; the disease is non-small cell lung carcinoma.